Harrow is topping off a busy couple of weeks by announcing the launch of an access and affordability program for several of its branded products across the United States.
Key to this program: A new strategic partnership with GoodRx, a U.S.-based prescription savings platform.
I’m here for these discounts … but first, talk about GoodRx.
The U.S.-based healthcare company operates via a telemedicine platform to provide patients and healthcare professionals (HCPs) with a free service for finding low-priced prescription drugs at local pharmacies.
These services, available via website and digital app, include:
- Comparison of prescription drug prices (brand name versus generic)
- Coupons for discounted drug prices
- Telehealth with online physician consultations for users
- Medical testing
In other words: GoodRx is all about the discounts.
Excellent. Now to this new program.
The Access and Affordability Program is specifically designed to target price reductions on a select number of Harrow’s ophthalmic products—with the intent to address “cost barriers that too often limit patient access,” the company stated.
Since the program kicked off this week, the following products have had price cuts:
- VIGAMOX (moxifloxacin hydrochloride ophthalmic suspension) 0.5%
- MAXIDEX (dexamethasone ophthalmic suspension) 0.1%
To note: Additional products are undergoing analysis for potential inclusion in this.
What else does this partnership entail?
GoodRx is also providing a cash-pay alternative for the purchase of the following Harrow products (including those two mentioned above):
- FLAREX (fluorometholone acetate ophthalmic suspension) 0.1%)
- ILEVRO (nepafenac ophthalmic suspension) 0.3%
- TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05%
- VEVYE (cyclosporine ophthalmic solution) 0.1%
- ZERVIATE (cyclosporine ophthalmic emulsion) 0.1%
About cash-pay alternatives: These are any methods of payment used in lieu of physician cash (ie: credit or debit cards, digital wallets like Apple or Google Play, and online payment platforms such as PayPal or Venmo).
- In this case: Patients are given an "alternative" to standard insurance with discounted pricing via GoodRx.
So how can patients get these discounts?
By heading over to GoodRx’s website or mobile app to search for participating pharmacies near them and access the discounts directly.
Sounds simple enough ... now, what else has Harrow been up to?
As we reported earlier this week, the company:
- Kicked off a multi-year partnership with Asembia to expand access to 10+ of its ophthalmic branded products across the U.S.
- Announced that VEVYE (cyclosporine ophthalmic solution) 0.1% will be included in key formularies managed by Medicare Part D beneficiaries.